Home › Compare › LBTD vs MRK

LBTD vs MRK: Dividend Comparison 2026

LBTD yields 20000.00% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LBTD wins by $52481917574412746752.00M in total portfolio value
10 years
LBTD
LBTD
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full LBTD calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — LBTD vs MRK

📍 LBTD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLBTDMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LBTD + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
LBTD pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LBTD
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, LBTD beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LBTD + MRK for your $10,000?

LBTD: 50%MRK: 50%
100% MRK50/50100% LBTD
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

LBTD
No analyst data
Altman Z
-29.2
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LBTD buys
0
MRK buys
0
No recent congressional trades found for LBTD or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLBTDMRK
Forward yield20000.00% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$52481917574412746752.00M ✓$30.7K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00 ✓$950.29
Total dividends collected$52448189483771600896.00M ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LBTD vs MRK ($10,000, DRIP)

YearLBTD PortfolioLBTD Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,192$351.54+$2.00M → LBTD
2$377,983,225$375,831,775.70$12,524$392.70+$377.97M → LBTD
3$66,433,479,469$66,029,037,418.28$14,015$438.65+$66433.47M → LBTD
4$10,916,985,471,987$10,845,901,648,955.73$15,682$489.96+$10916985.46M → LBTD
5$1,677,384,363,769,318$1,665,703,189,314,291.80$17,547$547.23+$1677384363.75M → LBTD
6$240,985,175,079,139,100$239,190,373,809,905,920.00$19,632$611.16+$240985175079.12M → LBTD
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$21,963$682.53+$32373573631143.68M → LBTD
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$24,571$762.18+$4066766648320630.00M → LBTD
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$27,486$851.08+$477730483406513344.00M → LBTD
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$30,745$950.29+$52481917574412746752.00M → LBTD

LBTD vs MRK: Complete Analysis 2026

LBTD — Stock

Lotus Bio-Technology Development Corp., a bio-technology development company, focuses on refining organic materials, and production of natural consumer related products in China. The company was formerly known as Starflick.com and changed its name to Lotus Bio-Technology Development Corp. in April 2016. Lotus Bio-Technology Development Corp. was founded in 2011 and is based in Cave Creek, Arizona.

Full LBTD Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this LBTD vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LBTD vs SCHDLBTD vs JEPILBTD vs OLBTD vs KOLBTD vs MAINLBTD vs JNJLBTD vs ABBVLBTD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.